Antitumour metallocenes: Structure-activity studies and interactions with biomolecules

被引:210
作者
Harding, MM [1 ]
Mokdsi, G [1 ]
机构
[1] Univ Sydney, Sch Chem F11, Sydney, NSW 2006, Australia
关键词
D O I
10.2174/0929867003374066
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The metallocene dihalides are a relatively new class of small, hydrophobic organometallic anticancer agents that exhibit antitumour properties against numerous cell lines including leukemias P388 and L1210, colon 38 and Lewis lung carcinomas, B16 melanoma, solid and fluid Ehrlich ascites tumours and several human colon and lung carcinomas transplanted into athymic mice. Titanocene dichloride 1 has been the most widely studied metallocene and the drug is currently in phase II clinical trials. Formation of metallocene-DNA complexes has been implicated in the mechanism of antitumour properties of the metallocenes, as both titanocene dichloride 1 and vanadocene dichloride 2 inhibit DNA and RNA synthesis, and titanium and vanadium accumulate in nucleic acid-rich regions of tumour cells. However, in contrast to the well characterized platinum-based anticancer drugs, the active species responsible for antitumour activity in vivo has not been identified and the mechanism whereby irreparable DNA damage and/or structural modification of DNA or other cellular targets occurs is poorly understood. This review will focus on recent studies that have been carried out in order to identify the biologically active species and more fully understand the molecular level mechanism of action of the metallocene dihalides. Studies with nucleotides, oligonucleotides, DNA and proteins including topoisomerases, protein kinase C and transferrin have provided important insight into potential cellular transport mechanisms and the interaction of metallocenes with biomolecular targets. New structure activity studies including the design of hydrolytically stable metallocenes and the preparation of highly water soluble amino acid analogues have not led to improved anticancer activity of titanocene dichloride 1. The vastly different chemical and hydrolytic stability of each of the metallocenes points to a unique mechanism of action of each metallocene in vivo.
引用
收藏
页码:1289 / 1303
页数:15
相关论文
共 76 条
[1]  
Berdel W. E., 1994, Journal of Cancer Research and Clinical Oncology, V120, pR172
[2]   Anti-proliferative activity and mechanism of action of titanocene dichloride [J].
Christodoulou, CV ;
Eliopoulos, AG ;
Young, LS ;
Hodgkins, L ;
Ferry, DR ;
Kerr, DJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2088-2097
[3]   Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer [J].
Christodoulou, CV ;
Ferry, DR ;
Fyfe, DW ;
Young, A ;
Doran, J ;
Sheehan, TMT ;
Eliopoulos, A ;
Hale, K ;
Baumgart, J ;
Sass, G ;
Kerr, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2761-2769
[5]   AQUO COMPLEXES OF TITANOCENE [J].
DOPPERT, K .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 1979, 178 (02) :C3-C4
[6]  
DOPPERT K, 1980, MAKROMOL CHEM-RAPID, V1, P519
[7]   TRANSITION-METAL COMPLEXES AS LIGANDS - PREPARATION OF MIXED TRANSITION-METAL COMPLEXES OF NIOBIUM WITH NICKEL, PALLADIUM, PLATINUM, OR MOLYBDENUM [J].
DOUGLAS, WE ;
GREEN, MLH .
JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1972, (16) :1796-&
[8]  
Friedrich M, 1998, EUR J GYNAECOL ONCOL, V19, P333
[9]  
Guo M, 1999, J INORG BIOCHEM, V74, P150
[10]   Competitive binding of the anticancer drug titanocene dichloride to N,N-ethylenebis(o-hydroxyphenylglycine) and adenosine triphosphate:: a model for TiIV uptake and release by transferrin [J].
Guo, ML ;
Sadler, PJ .
JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 2000, (01) :7-9